DJIA 17,244.00 87.15 0.51%
NASDAQ 4,586.40 24.21 0.53%
S&P 500 2,009.17 7.60 0.38%
market minute promo

11.20 -0.10 (-0.88%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

BCRX $11.20 -0.88%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $11.35
Previous Close $11.30
Daily Range $11.02 - $11.49
52-Week Range $4.55 - $14.62
Market Cap $803.7M
P/E Ratio -17.94
Dividend (Yield) $0.00 (0.0%)
Volume 311,209
Average Daily Volume 1,091,106
Current FY EPS -$0.84

Sector

Healthcare

Industry

Drugs

BioCryst Pharmaceuticals, Inc. (BCRX) Description

A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections. Website: http://www.biocryst.com/

News & Commentary Rss Feed

This Week in Biotech: VIVUS Attracts Buyout Interest While BioCryst Wows Investors

One mega-merger falls through the cracks, another struggling biotech draws buyout interest, and three biotechs deliver impressive clinical results.

BioCryst Receives Additional NIAID Funding For Manufacture and Development Of BCX4430, $19.9M Has B

BioCryst Receives Additional NIAID Funding For Manufacture and Development Of BCX4430, $19.9M Has Been Awarded To Date Under The Contract

Momentum Stocks Showing Weakness

Ebola: Desperate Days Ahead

Biotechs With Upside Target Ebola And Liver Disease: MLV's Vernon Bernardino

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

BioCryst Pharmaceuticals, Inc. Announces RAPIVAB Trial Results For The Treatment Of Influenza At The

BioCryst Pharmaceuticals, Inc. Announces RAPIVAB Trial Results For The Treatment Of Influenza At The ICAAC 2014 Meeting

BioCryst Announces RAPIVAB Trial Results For The Treatment Of Influenza At The ICAAC 2014 Meeting

BioCryst Pharmaceuticals, Inc. Sinks; WHO Notes Ebola Safety Data Unavailable

BioCryst's Ebola Candidate Moving to Efficacy Study Soon - Analyst Blog

BioCryst To Present Peramivir Trial Results For The Treatment Of Influenza At The ICAAC 2014 Meeting

See More BCRX News...

BCRX's Top Competitors

BCRX $11.20 (-0.88%)
Current stock: BCRX
AMGN $140.79 (0.06%)
Current stock: AMGN
GILD $104.63 (0.76%)
Current stock: GILD
BIIB $327.64 (0.02%)
Current stock: BIIB